Asia-Pacific Pharmaceutical Gelatin Market Size, Share, Trends & Growth Forecast Report By Function, By Source, By Application, and By Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) – Industry Analysis and Forecast, 2026 to 2034
The APAC Pharmaceutical Gelatin Market size was valued at USD 521.09 billion in 2024 and is anticipated to reach USD 755.91 billion by 2033, growing at a CAGR of 4.22% from 2024 to 2033. The market is gaining momentum due to the rising demand for remote cardiac care, the growing burden of cardiovascular diseases, and technological advancements in AI-powered diagnostics and wearable cardiac monitoring devices.
The APAC Pharmaceutical Gelatin Market was valued at USD 543.08 billion in 2025, is estimated to reach USD 566.00 billion in 2026, and is projected to reach USD 787.81 billion by 2034, growing at a CAGR of 4.22% from 2026 to 2034.
Pharmaceutical gelatin is a protein derivative obtained primarily from collagen found in animal bones, skin, and connective tissues. It plays a crucial role in the pharmaceutical industry as a gelling agent, binder, and encapsulating material for both hard and soft capsules. In the Asia-Pacific (APAC) region, pharmaceutical gelatin has become integral to drug delivery systems, especially in oral dosage forms. The market encompasses various types of gelatin, including bovine, porcine, and more recently, fish-based and plant-based alternatives aimed at addressing religious and dietary concerns.
The demand for pharmaceutical gelatin in the APAC region has been significantly influenced by the robust growth of the pharmaceutical industry in countries such as India, China, Japan, and South Korea. This expansion has directly stimulated the need for high-quality excipients like gelatin.
Apart from these, the Indian pharmaceutical industry exported medicines worth over USD 25 billion in 2023, contributing to nearly 3.5% of global pharma trade, as per data published by the Department of Pharmaceuticals, India. Such export volumes underscore the increasing domestic consumption of raw materials, including pharmaceutical gelatin. As per the China Pharmaceutical and Chemical Import and Export Corporation, China accounted for over 20% of the global production of active pharmaceutical ingredients (APIs) in 2023, further reinforcing the need for compatible excipients like gelatin in capsule manufacturing.
The rapid expansion of the generic drug industry, particularly in India and China, is one of the primary drivers fueling the APAC Pharmaceutical Gelatin Market. These countries are among the top global suppliers of affordable medicines, with India being known as the "pharmacy of the world." As per the Indian Brand Equity Foundation, India supplies over 20% of the global generics market and caters to nearly 50% of global vaccine demand. Generics often require cost-effective yet reliable excipients, and gelatin fits this requirement perfectly due to its biocompatibility, low cost, and excellent binding properties.
In addition, regulatory bodies like the U.S. Food and Drug Administration (FDA) have approved numerous Indian and Chinese manufacturers for the export of generic drugs, which has increased their production capacities.
Moreover, the rise in chronic diseases and the growing geriatric population have amplified the demand for affordable medications. As per the World Health Organization (WHO), non-communicable diseases account for over 60% of all deaths in the Asia-Pacific region. This health burden necessitates large-scale production of medicines, thereby boosting the usage of pharmaceutical gelatin.
The rising popularity of softgel capsules in the nutraceutical industry is another major driver of the APAC Pharmaceutical Gelatin Market. Softgels are widely used for delivering vitamins, supplements, oils, and herbal extracts due to their ease of swallowing, enhanced bioavailability, and better shelf life.
China and India lead this trend, driven by rising consumer awareness about preventive healthcare and wellness. As per the China Nutrition Care Association, nutraceutical sales in China reached USD 32 billion in 2023, with softgel formats accounting for nearly 40% of total unit sales. Similarly, in India, the nutraceutical market grew by 17% in 2023 compared to the previous year, according to the Associated Chambers of Commerce and Industry of India (ASSOCHAM).
Softgel capsules predominantly use gelatin as the shell material. With the preference for halal and kosher-certified products on the rise, there has also been a shift toward alternative gelatin sources such as fish and plant-based options. Nevertheless, traditional gelatin remains dominant due to its superior film-forming properties. This growing application in nutraceuticals is thus driving sustained demand for pharmaceutical-grade gelatin across the APAC region.
Stringent regulations and cultural sensitivities surrounding the use of animal-derived gelatin, is a significant restraint in the APAC Pharmaceutical Gelatin Market. Many consumers in the region, particularly in Muslim-majority countries such as Indonesia and Malaysia, avoid products containing porcine or bovine gelatin due to religious beliefs.
This has created a challenge for pharmaceutical companies that traditionally rely on bovine and porcine gelatin. Regulatory authorities in several APAC countries mandate clear labeling and certification for products containing animal-derived ingredients. As per the Halal Development Corporation Malaysia, compliance with halal standards can increase production costs, impacting smaller manufacturers.
Furthermore, sourcing alternatives such as fish gelatin or plant-based hydrocolloids involves higher costs and technical complexities. Besides, these alternatives may not always offer the same mechanical and functional properties required for pharmaceutical applications.
As a result, while the market is evolving toward alternative gelatin sources, the transition is slow due to regulatory hurdles, consumer skepticism, and economic feasibility. This creates a notable constraint on the widespread adoption of traditional pharmaceutical gelatin in certain parts of the APAC region.
The volatility in raw material prices and disruptions in the supply chain, especially following recent global events, is another critical restraint affecting the APAC Pharmaceutical Gelatin Market. Gelatin is derived from animal by-products such as cattle bones and pigskins, which are closely linked to the meat and leather industries. Any disruption in livestock production or changes in agricultural policies can significantly impact gelatin availability and pricing.
For example, in 2023, China faced a shortage of bovine hides due to African swine fever outbreaks, which reduced pork production by 14% compared to 2022, as reported by the Ministry of Agriculture and Rural Affairs of China. This resulted in a 22% increase in the price of bovine gelatin within the domestic market during the same period, according to the China Gelatin Industry Association.
Moreover, geopolitical tensions and trade restrictions have affected the import of raw materials. Australia and New Zealand, key exporters of bovine hides to China and India, experienced logistical bottlenecks due to pandemic-related border closures and labor shortages.
These fluctuations create uncertainty for manufacturers who depend on stable inputs for consistent production. Smaller players, in particular, face difficulties in managing procurement costs, leading to reduced profit margins and delayed product launches. Thus, supply chain instability continues to pose a substantial barrier to the smooth growth of the pharmaceutical gelatin market in the APAC region.
The growing investment in biopharmaceutical research and development (R&D) is an emerging opportunity in the APAC Pharmaceutical Gelatin Market. Countries like South Korea, Singapore, and Australia are increasingly focusing on innovation in biologics, vaccines, and targeted therapies, where gelatin serves as a vital excipient in formulation stability and delivery mechanisms.
Notably, South Korea allocated 4.8% of its GDP to R&D in 2023, one of the highest globally, as per the National Science and Technology Council of South Korea. This investment has fueled advancements in biopharmaceuticals, many of which require specialized delivery systems involving gelatin-based components.
Moreover, Singapore has positioned itself as a regional hub for biopharmaceutical innovation. As per the Agency for Science, Technology and Research (A*STAR), Singapore attracted over USD 1.2 billion in biopharma investments in 2023, supporting the establishment of new manufacturing and R&D centers. These developments are likely to expand the scope of pharmaceutical gelatin applications beyond traditional uses into advanced drug delivery systems.
Moreover, the ongoing development of lyophilized (freeze-dried) injectables and nasal vaccines has renewed interest in gelatin’s cryoprotective properties.
With increasing consumer awareness around ethical consumption and sustainability, the APAC Pharmaceutical Gelatin Market is witnessing a growing shift toward plant-based and alternative gelatin solutions. This presents a promising opportunity for manufacturers willing to innovate and diversify their product portfolios.
Vegetarian and vegan lifestyles are gaining popularity across urban populations in India, Australia, and Southeast Asia.
To cater to this demand, companies are investing in the development of plant-based gelatin alternatives derived from seaweed (agar-agar), algae (carrageenan), and microbial fermentation processes. For instance, Japanese firm Nitta Gelatin launched a line of plant-based gelatin products in 2023 specifically designed for pharmaceutical applications, citing improved solubility and lower allergenic risk.
Moreover, governments in the APAC region are encouraging sustainable sourcing practices. As consumer preferences evolve and regulatory frameworks adapt, the alternative gelatin segment is expected to experience accelerated growth, offering fresh avenues for expansion in the APAC pharmaceutical industry.
Despite growing demand for alternative gelatin sources, the APAC Pharmaceutical Gelatin Market faces significant challenges due to technological limitations in producing viable substitutes that match the functional properties of traditional animal-derived gelatin. While plant-based and microbial gelatin options are gaining traction, they often fall short in terms of gelling strength, viscosity, and thermal stability—key attributes required for pharmaceutical applications.
Furthermore, the extraction and purification processes for alternative gelatins are more energy-intensive and costly. For example, producing agar-agar from red seaweed requires extensive drying and refining steps, increasing production time and operational costs.
In addition, scaling up microbial fermentation-based gelatin production remains a challenge. Although recombinant DNA technology enables the synthesis of human-like gelatin, it requires highly controlled bioreactors and specialized downstream processing equipment, which are currently limited in APAC.
These technological constraints hinder the seamless integration of alternative gelatins into mainstream pharmaceutical manufacturing, posing a major challenge for market growth in the near term.
Maintaining compliance with stringent quality and safety standards represents another major challenge for the APAC Pharmaceutical Gelatin Market. As a critical excipient in drug formulations, gelatin must meet rigorous international pharmacopeial standards such as those set by the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and the International Society for Pharmaceutical Engineers (ISPE).
In APAC, regulatory authorities such as the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and the Therapeutic Goods Administration (TGA) in Australia enforce strict guidelines on traceability, purity, and microbiological testing of gelatin used in pharmaceuticals.
Moreover, ensuring BSE (Bovine Spongiform Encephalopathy) and TSE (Transmissible Spongiform Encephalopathy) free certification has become a prerequisite for exporting animal-derived gelatin. Countries like India and China face additional scrutiny due to past incidents related to livestock disease outbreaks. As per the World Organisation for Animal Health (WOAH), China recorded two cases of atypical BSE in cattle in 2023, prompting stricter import checks from EU nations.
Meeting these global benchmarks requires substantial investment in quality control infrastructure, documentation systems, and staff training. Small and medium-sized enterprises (SMEs) in the APAC gelatin industry often struggle with these requirements, limiting their ability to compete in export markets. Consequently, adherence to evolving quality standards remains a persistent hurdle for the pharmaceutical gelatin industry in the region.
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Covered | By Function, Source, Application and Country. |
| Various Analyses Covered | Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Country Covered | China, India, Japan, South Korea, Australia, New Zealand, Thailand, Indonesia, Philippines, Vietnam, Singapore, Rest of APAC. |
| Market Leader Profiled | Rousselot, Nitta Gelatin Inc., Capsugel, Catelent Inc., Norland Products Inc, Tessenderlo Group. |
The gelling agents segment dominated the APAC Pharmaceutical Gelatin Market by accounting for 45.6% of total consumption in 2024. The widespread use of gelatin in capsule manufacturing, particularly in soft and hard capsules, where it serves as a key structural component is primarily attributed to the dominance of gelling agents segment.
Further, the rise in contract manufacturing organizations (CMOs) across Southeast Asia has increased the need for standardized excipients like gelatin. These facilities rely heavily on gelatin for encapsulation, contributing to its dominant position in the functional segment.
Technological advancements such as enteric-coated formulations also require high-quality gelatin to maintain structural integrity under varying pH conditions. This has further solidified the gelling agents segment’s leadership in the APAC pharmaceutical gelatin landscape.
The stabilizers segment is projected to grow at the fastest CAGR of 9.1% from 2025 to 2033 within the APAC Pharmaceutical Gelatin Market. The increasing complexity of drug formulations, particularly in biologics and vaccines, which require enhanced stability during storage and transportation is driving the rapid growth of stabilizers segment.
Moreover, the expansion of vaccine manufacturing in India, especially post-pandemic, has significantly boosted demand for gelatin as a stabilizing agent.
With rising R&D investments in temperature-sensitive therapeutics and biosimilars, the stabilizers function of pharmaceutical gelatin is expected to gain even greater traction across the APAC region.
The bovine hides segment was the largest source in the APAC Pharmaceutical Gelatin Market by capturing an estimated 40.1% of total volume in 2024. The superior gelling strength and purity offered by bovine-derived gelatin, making it highly suitable for pharmaceutical applications is propelling the growth of bovine hides segment.
China remains the leading consumer of bovine hide-based gelatin. The country’s vast cattle population ensures a steady supply of raw materials for gelatin extraction.India also contributes significantly to this segment, leveraging its extensive livestock industry. Indian manufacturers exported over USD 45 million worth of pharmaceutical gelatin in 2023, primarily derived from bovine sources.
Furthermore, regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) have stringent sourcing guidelines that favor bovine hides from controlled regions, enhancing their global acceptability.
The fish-based gelatin segment is anticipated to register the highest CAGR of 10.3% from 2025 to 2033. Rising consumer preference for non-animal alternatives that align with halal, kosher, and vegan standards is driving the development of fish-based gelatin segment.
Indonesia, the world's largest Muslim-majority country, has seen a surge in demand for halal-certified pharmaceutical products. As per the Indonesian Halal Certification Agency (BPJPH), over 60,000 food and drug products received halal certification in 2023, many of which used fish gelatin instead of porcine or bovine derivatives.
In addition, Japan leads in marine-based resource utilization. Australia has also emerged as a key player in sustainable aquaculture practices. These factors contribute to the accelerated adoption of fish-based gelatin, positioning it as the fastest-growing source segment in the APAC pharmaceutical market.
The soft capsules segment represented the largest application in the APAC Pharmaceutical Gelatin Market by holding 38.6% of the total share in 2024. The growing popularity of softgel formats in both prescription and over-the-counter medications, particularly in nutraceuticals and hormone therapies is largely attributed to the dominance of soft capsules segment.
Countries like Malaysia and Thailand have witnessed a boom in private-label supplement brands, which predominantly utilize softgel technology for oil-based formulations.
Similarly, China’s State Administration for Market Regulation recorded a growth in soft capsule imports by health supplement firms in 2023, reflecting strong domestic and international demand.
Moreover, softgels offer advantages such as taste masking, ease of swallowing, and enhanced bioavailability, which make them ideal for pediatric and geriatric populations. With rising disposable incomes and health awareness in APAC, the soft capsules segment continues to drive the pharmaceutical gelatin market forward.
The microencapsulation segment is the fastest-growing application in the APAC Pharmaceutical Gelatin Market and is expanding at a CAGR of 11.2%. This growth is driven by the increasing use of microencapsulated APIs in controlled-release formulations, targeted drug delivery, and flavor-masking applications.
South Korea has strong focus in microencapsulation technology. Korean pharmaceutical firms are increasingly adopting gelatin-based microcapsules for gastro-resistant formulations and time-released supplements.
In Australia, the Therapeutic Goods Administration (TGA) approved several microencapsulated drugs in 2023, particularly in oncology and diabetes management.
Japan has also made significant strides in this area, with companies like Eisai integrating gelatin microcapsules into neuropharmaceuticals to enhance blood-brain barrier penetration.
This technological shift toward precision medicine and advanced delivery systems is propelling the microencapsulation segment to become the most dynamic application area for pharmaceutical gelatin in APAC.
China led the APAC Pharmaceutical Gelatin Market by contributing 28.4% of total regional consumption in 2024. The country’s domestic demand for pharmaceutical gelatin is primarily driven by the booming nutraceutical and traditional Chinese medicine sectors. Apart from these, government initiatives such as the "Made in China 2025" strategy have spurred investment in advanced pharmaceutical manufacturing, boosting the usage of high-purity gelatin in capsule and tablet coatings. Despite challenges related to raw material availability and regulatory scrutiny, China remains a dominant force in shaping the APAC pharmaceutical gelatin landscape.
India is a significant player in the APAC Pharmaceutical Gelatin Market. Known as the “pharmacy of the world,” India exports medicines to over 200 countries and contributed nearly 3.5% of global pharma trade in 2023, as per the Department of Pharmaceuticals.
The Indian pharmaceutical industry relies heavily on gelatin for capsule manufacturing, especially in the generic drug and nutraceutical segments. Over 1.5 lakh new generic drug formulations were launched in 2023, each requiring excipients like gelatin for encapsulation.
Moreover, India has emerged as a major exporter of halal-certified gelatin, catering to Middle Eastern and Southeast Asian markets. Companies like Gujarat Ambuja Exports and Nitin Packers have invested in alternative gelatin processing plants to meet evolving dietary preferences.
Japan holds a notable share of the APAC Pharmaceutical Gelatin Market, driven by its advanced pharmaceutical industry and high standards for drug formulation. The country is a major innovator in biologics, targeted therapies, and specialty medicines, all of which incorporate gelatin as a stabilizer and excipient.
Besides, the aging population—a significant portion of whom are aged 65 and above—has led to increased demand for chronic disease treatments, which often employ gelatin in sustained-release mechanisms.
Japanese firms like Nitta Gelatin and Nippon Meat Packers have expanded their capabilities in producing high-purity and recombinant gelatin, aligning with global trends toward safety and traceability. Despite its relatively smaller size compared to China and India, Japan remains a critical market due to its emphasis on quality and innovation.
South Korea is a key player in the APAC Pharmaceutical Gelatin Market, supported by its thriving biopharmaceutical sector and growing focus on personalized medicine. The country is home to leading pharmaceutical firms such as Samsung Bioepis and Celltrion, which are increasingly using gelatin in novel drug delivery systems.
A significant portion of these exports includes biologics and injectables that depend on gelatin for stabilization and lyophilization.
Moreover, South Korea’s regulatory environment encourages the development of high-quality excipients. The Ministry of Food and Drug Safety (MFDS) mandates rigorous testing for gelatin used in pharmaceuticals, ensuring compliance with international pharmacopeias.
Government-backed R&D programs have also facilitated the adoption of plant-based and microbial gelatin alternatives.
Australia captures descent share of the APAC Pharmaceutical Gelatin Market, driven by a combination of domestic pharmaceutical manufacturing and import activities. The country’s pharmaceutical industry is characterized by high regulatory standards and a growing emphasis on health and wellness.
As per the Australian Nutraceutical Association, the local nutraceutical market reached AUD 5.4 billion in 2023, with softgels accounting for a significant share.
Australia also plays a pivotal role in supplying raw materials for gelatin production to other APAC countries. As per the Australian Bureau of Agricultural and Resource Economics and Sciences (ABARES), beef hide exports to Asia increased in 2023, supporting gelatin manufacturing in China and India.
With a strong focus on sustainability and ethical sourcing, Australia is witnessing increased interest in plant-based gelatin alternatives. The Department of Agriculture, Fisheries and Forestry allocated AUD 25 million in 2023 to support research into alternative proteins, signaling a shift toward more diverse gelatin applications in the pharmaceutical sector.
Rousselot, Nitta Gelatin Inc., Capsugel, Catelent Inc., Norland Products Inc, Tessenderlo Group, Sterling Gelatin, Roxlor LLC, Weishardt, and Gelita AG are a few of the noteworthy companies operating in the APAC pharmaceutical gelatin market.
The competition in the APAC Pharmaceutical Gelatin Market is characterized by a blend of established global players and emerging regional manufacturers striving to capture a larger market share. As pharmaceutical production expands across Asia, driven by rising healthcare expenditure and growing generic drug manufacturing, demand for high-quality gelatin continues to surge. This has led to intensified rivalry among suppliers seeking to differentiate themselves through product innovation, purity standards, and customization capabilities. Companies are increasingly focusing on sustainability and ethical sourcing to align with evolving consumer expectations and regulatory norms. At the same time, the push toward alternative gelatin sources is prompting firms to invest in research and development to stay ahead in the market. With increasing scrutiny around raw material sourcing and traceability, competitive positioning now hinges not only on pricing but also on compliance, transparency, and the ability to offer halal-, kosher-, and vegan-certified options. This dynamic environment fosters continuous innovation and strategic expansion, shaping the future landscape of the APAC pharmaceutical gelatin industry.
One of the leading players in the APAC Pharmaceutical Gelatin Market is Rousselot , a global supplier of gelatin solutions for pharmaceutical applications. The company has a strong presence across Asia, particularly in China and India, where it supplies high-quality bovine and porcine gelatin to major drug manufacturers. Rousselot is known for its innovation in alternative gelatin sources and invests heavily in R&D to meet evolving regulatory and consumer demands.
Another key player is Weishardt Group , a France-based company with a significant footprint in the APAC region. Weishardt offers customized gelatin products tailored for pharmaceutical uses, including capsule coatings and controlled-release formulations. Its strategic partnerships with local manufacturers in Southeast Asia have helped expand its regional influence and enhance product availability.
The third major player is Nitta Gelatin Inc. , a Japanese company that plays a pivotal role in supplying pharmaceutical gelatin across East Asia. Nitta Gelatin focuses on sustainable sourcing and has developed plant-based alternatives to cater to halal and vegan preferences. The company's emphasis on quality assurance and technological advancement positions it as a trusted partner for pharmaceutical firms in Japan and beyond.
One major strategy adopted by key players in the APAC Pharmaceutical Gelatin Market is product diversification through alternative gelatin development . Companies are investing in research to produce plant-based, microbial, and fish-derived gelatin to meet diverse religious and dietary preferences, especially in Muslim-majority countries.
Another prominent approach is strategic collaborations and partnerships with regional pharmaceutical manufacturers . By aligning with local drug producers, gelatin suppliers ensure consistent demand and gain insights into specific formulation requirements, enhancing their ability to offer tailored solutions.
A third critical strategy involves expanding production facilities and strengthening supply chain networks across APAC . Manufacturers are setting up new processing units in emerging markets like Vietnam and Thailand to reduce dependency on imports, improve cost efficiency, and ensure timely delivery of high-quality gelatin to pharmaceutical clients.
In January 2025, Nitta Gelatin Inc. launched a new line of plant-based pharmaceutical gelatin in Japan, targeting the growing demand for vegetarian-friendly and halal-certified excipients in drug formulations.
In May 2025, Rousselot expanded its distribution network in Southeast Asia by partnering with a local distributor in Indonesia to enhance its reach and responsiveness to pharmaceutical companies in the region.
In September 2025, Weishardt Group introduced a new gelatin purification technology at its facility in China, aimed at improving product consistency and meeting stringent international quality standards for pharmaceutical use.
In February 2025, PB Gelatins entered into a collaboration with an Indian pharmaceutical manufacturer to co-develop customized gelatin solutions for softgel capsule production, reinforcing its position in the fast-growing nutraceutical sector.
In June 2025, Gelita AG opened a regional technical service center in South Korea to support pharmaceutical clients with formulation expertise, regulatory guidance, and application-specific testing for gelatin-based products.
This market research report on the APAC Pharmaceutical Gelatin Market has been segmented and sub-segmented into the following categories.
By Function
By Source
By Application
By Country
Frequently Asked Questions
Pharmaceutical gelatin is a protein-based compound derived from collagen, commonly used in the manufacture of capsules, tablets, wound dressings, and vaccines. In the APAC region, it is widely used due to its affordability, biocompatibility, and versatility in drug delivery systems.
Key growth drivers include are Expanding pharmaceutical manufacturing in India and China Rising demand for capsules and soft gels Increasing geriatric population Growing adoption of nutraceuticals and personalized medicine
Major contributors include are China – Large domestic pharma industry India – Rapidly growing generic drug sector Japan – High consumption of soft gelatin capsules South Korea and Australia – Advanced healthcare systems and R&D
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region